The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).

Peer Review reports

Original Submission
2 Dec 2022	Submitted	Original manuscript
14 Feb 2023	Author responded	Author comments - Glenn Bauman
Resubmission - Version 2
14 Feb 2023	Submitted	Manuscript version 2
8 Mar 2023	Reviewed	Reviewer Report
31 Mar 2023	Reviewed	Reviewer Report
5 Apr 2023	Author responded	Author comments - Glenn Bauman
Resubmission - Version 3
5 Apr 2023	Submitted	Manuscript version 3
13 Apr 2023	Reviewed	Reviewer Report
Resubmission - Version 4
	Submitted	Manuscript version 4
Publishing
14 Apr 2023	Editorially accepted
20 Apr 2023	Article published	10.1186/s12885-023-10851-0

Back to article page